BFCH Plans 10-Fold Increase in Regulation A Offering Price to $0.001 Per Share

UNLOCKD plans to seek SEC qualification to raise its Regulation A offering price tenfold, from $0.0001 to $0.001 per share. At the proposed price, raising $100,000 would require about 100 million shares versus 1 billion currently, a 90% reduction in new issuance; the change is not yet qualified and does not represent an independent company valuation. The company cited completed acquisitions including EVERMIND, Ancient Extracts USA, and 1ENERGY, while its proposed Ancient Extracts UK acquisition could add nearly $1 million in annualized revenue upon closing, subject to financing and other conditions.

Analysis

The proposed price change is a financing term, not evidence of a 10x increase in enterprise value or improved funding access. The key economic test is whether investors will subscribe at the revised price and whether proceeds translate into operating assets that generate cash. If demand is weak, a higher stated offering price may simply delay financing; if the company must return to lower-priced equity or other costly funding, the dilution and authorized-share constraint remain.

For existing holders, fewer shares issued per dollar is beneficial only at equal capital raised and comparable terms. It does not remove dilution from future rounds, nor establish that the offering price is close to the trading price. The proposed UK acquisition adds execution and financing risk: annualized revenue is not equivalent to collected revenue, gross profit, or cash flow, and any operating benefit depends on closing, integration, and working-capital needs.

Near term, the main catalysts are the SEC filing/qualification and evidence of actual subscriptions; either could change the credibility of the financing plan. Over 1–3 months, verify acquisition closing terms, funding source, and reported cash conversion. Over 6–18 months, commercial execution matters more than the offering-price headline. The contrarian read is that the share-count arithmetic is being emphasized because capital needs and authorized capacity may be binding; absent verified demand and operating results, this is not yet a de-risking event. OTC liquidity and potential inability to borrow make a directional short unattractive without confirming execution and borrow availability.

Key Decisions for Investors

• No immediate directional trade: treat the announcement as a financing proposal, not a valuation catalyst. Avoid inferring fair value from the revised offering price.
• Set a filing-and-demand watch: reassess only after the amendment is qualified and the company discloses actual capital raised, subscription terms, and remaining authorized share capacity.
• Before underwriting the UK acquisition, verify closing, financing terms, audited revenue, gross margin, and working-capital requirements; do not value annualized revenue as earnings or cash flow.
• Falsification of the dilution-reduction thesis: failure to qualify the amendment, weak subscriptions at the revised price, subsequent lower-priced issuance, or acquisition funding that materially expands share issuance.